POTOMAC, Md.--(BUSINESS WIRE)--IGC Pharma, Inc. (NYSE American: IGC) (“IGC” or the “Company”) today announced a $3 million strategic investment from funds managed by Bradbury Asset Management (Hong Kong) Limited (“Bradbury”), a leading asset management firm.

马里兰州波托马克——（商业新闻短讯）——IGC Pharma，Inc.（纽约证券交易所美国代码：IGC）（“IGC”或“公司”）今天宣布从领先的资产管理公司Bradbury Asset Management（Hong Kong）Limited（“Bradbury”）管理的基金中进行300万美元的战略投资。

On March 22, 2024, the Company entered into a Share Purchase Agreement (the “SPA”) with Bradbury, subject to the terms and subject to the conditions set forth in the SPA. The investment is for approximately $3 million in gross proceeds at the March 21, 2024, closing price of $0.34. The funds will support general corporate purposes and the Company’s advancement of its investigational medicines including IGC-AD1..

2024年3月22日，公司与Bradbury签订了一份股份购买协议（“SPA”），该协议应符合SPA中规定的条款和条件。截至2024年3月21日，该投资的总收益约为300万美元，收盘价为0.34美元。这些资金将支持公司的一般用途以及公司对包括IGC-AD1在内的研究药物的进步。

The completion of the private placement is subject to customary closing conditions, including approval by the NYSE. Under the terms of the SPA, IGC will issue 8,823,529 shares of common stock. The shares are unregistered and are not immediately tradable.

私募的完成取决于惯例的交割条件，包括纽约证券交易所的批准。根据SPA条款，IGC将发行8823529股普通股。这些股票未经登记，不能立即交易。

Please note that this press release does not constitute an offer to sell or a solicitation of an offer to buy these securities. Furthermore, there shall be no sale of the securities in any state in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of the respective state..

请注意，本新闻稿不构成出售或邀请购买这些证券的要约。此外，在根据各自国家的证券法进行登记或取得资格之前，如果此类要约、招徕或出售将是非法的，则不得在任何国家出售证券。

About IGC Pharma Inc. (IGC):

关于IGC Pharma Inc.（IGC）：

IGC Pharma Inc. (“IGC”) is focused on Alzheimer's disease, developing innovative solutions to address this devastating illness. The Company's mission is to transform the landscape of Alzheimer's treatment with a robust pipeline of five promising drug candidates. IGC-AD1 and LMP target the hallmarks of Alzheimer's disease, including neuroinflammation, Aβ plaques, and neurofibrillary tangles.

IGC制药公司（“IGC”）专注于阿尔茨海默氏病，开发创新解决方案来应对这种毁灭性疾病。该公司的使命是通过五种有前途的候选药物的强大渠道来改变阿尔茨海默氏病治疗的格局。IGC-AD1和LMP靶向阿尔茨海默病的标志，包括神经炎症，Aβ斑块和神经原纤维缠结。

IGC-AD1 is currently undergoing a Phase 2 clinical trial for agitation in dementia associated with Alzheimer's (clinicaltrials.gov, CT05543681). TGR-63 disrupts the progression of Alzheimer's by targeting Aβ plaques. IGC-M3, currently in preclinical development, aims to inhibit the aggregation of Aβ plaques, potentially impacting early-stage Alzheimer's.

IGC-AD1目前正在进行与阿尔茨海默病相关的痴呆症激越的2期临床试验（clinicaltrials.gov，CT05543681）。TGR-63通过靶向Aβ斑块破坏阿尔茨海默病的进展。目前处于临床前开发阶段的IGC-M3旨在抑制Aβ斑块的聚集，从而可能影响早期阿尔茨海默氏病。

IGC-1C, also in preclinical stages, targets tau protein and neurofibrillary tangles, representing a forward-thinking approach to Alzheimer's therapy. In addition to its drug development pipeline, IGC Pharma seeks to leverage Artificial Intelligence (“AI”) for Alzheimer's research. Their AI projects encompass various areas, including clinical trial optimization and early detection of Alzheimer's..

IGC-1C也处于临床前阶段，靶向tau蛋白和神经原纤维缠结，代表了阿尔茨海默病治疗的前瞻性方法。除了药物开发渠道之外，IGC制药公司还寻求利用人工智能（AI）进行阿尔茨海默病研究。他们的人工智能项目涵盖各个领域，包括临床试验优化和阿尔茨海默氏病的早期检测。

Forward-Looking Statements:

前瞻性声明：

This press release contains forward-looking statements. These forward-looking statements are based largely on IGC Pharma’s expectations and are subject to several risks and uncertainties, certain of which are beyond IGC Pharma’s control. Actual results could differ materially from these forward-looking statements as a result of, among other factors, the Company’s failure or inability to commercialize one or more of the Company’s products or technologies, including the products or formulations described in this release, or failure to obtain regulatory approval for the products or formulations, where required, or government regulations affecting AI or the AI algorithms not working as intended or producing accurate predictions; general economic conditions that are less favorable than expected; the FDA’s general position regarding cannabis- and hemp-based products; and other factors, many of which are discussed in IGC Pharma’s U.S.

本新闻稿包含前瞻性声明。这些前瞻性陈述主要基于IGC Pharma的预期，并受到一些风险和不确定性的影响，其中某些风险和不确定性超出了IGC Pharma的控制范围。除其他因素外，由于公司未能或无法将公司的一种或多种产品或技术（包括本版本中描述的产品或配方）商业化，或未能在需要时获得产品或配方的监管批准，或影响AI的政府法规或AI算法未按预期工作或产生准确预测，实际结果可能与这些前瞻性陈述存在重大差异；总体经济状况不如预期；FDA关于大麻和大麻产品的一般立场；和其他因素，其中许多因素在IGC Pharma的美国进行了讨论。

Securities and Exchange Commission ('SEC') filings. IGC Pharma incorporates by reference the human trial disclosures and Risk Factors identified in its Annual Report on Form 10-K filed with the SEC on July 7, 2023, and Quarterly Report on Form 10-Q filed with the SEC on February 14, 2024, as if fully incorporated and restated herein.

美国证券交易委员会（“SEC”）备案。IGC Pharma通过引用将其2023年7月7日提交给SEC的10-K表格年度报告和2024年2月14日提交给SEC的10-Q表格季度报告中确定的人体试验披露和风险因素纳入其中，就像完全纳入并重申了本文一样。

Considering these risks and uncertainties, there can be no assurance that the forward-looking information contained in this release will occur..

考虑到这些风险和不确定性，无法保证本版本中包含的前瞻性信息会发生。